Authored by Clarion, now part of Lumanity
Dennis Chang, a Clarion principal, recently partnered with Dr. Keith Flaherty of MGH and Uciane Scarlett of Oxford Sciences Innovation to publish the following In Vivo article – A Tale Of Two Pipelines: The Promise And Pitfalls Of IO Exuberance And How To Rethink The Approach To Cancer Innovation.
The article was generated from discussions during last year’s Emerging Frontiers in Oncology Summit, which raised funds for Luke Timmerman’s Kilimanjaro Climb to Fight Cancer team for the Fred Hutchinson Cancer Research Center.
This thought piece acknowledges the exciting achievements of the immuno-oncology (I-O) field, while highlighting the inefficiencies of the current profusion of me-too I-O products and studies. Moreover, the piece outlines 3 ways in which we can pursue cancer innovation in a smarter manner: by rethinking our translational models, rethinking data ownership, and rethinking the paradigm for clinical development and clinical practice.
